home About Us People Portfolio News Contact Us Fund I Investor Login » Fund II Investor Login » Fund III Investor Login »

news

Tag: 2018

Jun6CRG Completes Financing Transaction with Fast Pace Urgent Care »


New York – June 6, 2018 – CRG, a leading healthcare investment firm, today announced a partnership with Fast Pace Urgent Care (“Fast Pace”), a leading provider of urgent care...

Read More »

Jun4Dynavax Reports Data for Phase 1b/2 Trial of SD-101 in Combination with KEYTRUDA® (pembrolizumab) in Advanced Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting »


-- Overall Response Rate (ORR) of 70% and 6-month Progression Free Survival (PFS) rate of 76% in Patients Naïve to Anti-PD-1 Treatment who Received the ≤ 2mg Dose of...

Read More »

May31T2 Biosystems Announces Pricing of Public O »


Lexington, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the pricing of an underwritten registered public offering of 6,100,000 shares of common stock at a public...

Read More »

May22BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board »


Raleigh, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct...

Read More »

May8GenomeDx Biosciences Announces Research Collaboration with Janssen Pharmaceuticals to Evaluate the Decipher® Classifier and Decipher GRID® for Drug Development »


San Diego – May 8, 2018 – GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced a research collaboration with Janssen Pharmaceuticals. As part of the agreement,...

Read More »

May1CRG Expands Investment Team and Appoints Todd Holmes as Principal »


Boulder, Colorado – May 1st, 2018 – CRG, a leading healthcare investment firm, today announced the appointment of Todd Holmes as Principal in the firm’s Boulder office. Mr. Holmes...

Read More »

Apr26Humana-Walmart Deal Would Be Brilliant On Many Levels: CRG’s Li »


April 26, 2018 - Bloomberg Markets AM with Pimm Fox and Lisa Abramowicz.   GUEST: Scott Li, principal at CRG, a healthcare private investment firm, to discuss investment opportunities in the healthcare...

Read More »

Apr24Valeritas Announces Pricing of $24 Million Public Offering of Common Stock »


Bridewater, N.J., April 24, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers patients with type 2 diabetes V-Go® Wearable...

Read More »

Apr18CRG Completes Planned Leadership Transition to Nathan Hukill »


-- Founder Charles Tate to serve as Chairman Emeritus --   Boulder, Colo. – April 18th, 2018 – CRG, a leading healthcare investment firm, today announced the completion of the...

Read More »

Apr6Cardiome Announces Amendment to Term Loan Agreement with CRG-Managed Funds »


Vancouver, April 6, 2018 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome" or the "Company") today announced that it has entered into a first amending...

Read More »

Apr4bioMérieux Reinforces its Offering of High Medical Value Immunoassay Biomarkers With the Acquisition of Astute Medical »


-- bioMérieux, a world leader in the field of in vitro diagnostics, announces today the acquisition of Astute Medical Inc., a company dedicated to improving the diagnosis...

Read More »

Mar20Cipher Pharmaceuticals and Cardiome Pharma Announce Strategic Transaction for Canadian Business Portfolio of Cardiome »


-- Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of $25.5 Million ...

Read More »

Mar1Corium Prices Offering of $100 Million of 5% Convertible Senior Notes »


Menlo Park, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced the...

Read More »

Feb26ViewRay Announces $59 Million Equity Financing »


-- Financing to Further Support Growth of MRIdian Linac --   Cleveland, Feb. 26, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's first and only clinical MRI-guided...

Read More »

Feb22GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer »


-- Decipher testing recognized as standard-of-care in management of prostate cancer patients --   San Diego – February 22, 2018 – GenomeDx Biosciences, a leader in the field of urologic...

Read More »

Feb20Dynavax Secures $175 Million in Non-Dilutive Debt Financing »


-- Proceeds to be Used to Commercialize HEPLISAV-B™ [Hepatitis B Vaccine (Recombinant), Adjuvanted] in United States and Advance Company's Immuno-Oncology Product Candidates --   -- Company Deploying HEPLISAV-B...

Read More »

Feb12Viveve Announces Closing of Public Offering of Shares of Common Stock »


Englewood, CO -- (Marketwired) -- 02/12/18 -- Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of its previously...

Read More »

Feb9Tandem Diabetes Care Announces Pricing of $60 Million Underwritten Public Offering of Common Stock »


San Diego --(BUSINESS WIRE) --Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today...

Read More »

Jan25Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBSC) in Adults »


NEW YORK- (BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) announced today that the U.S. Food and Drug Administration (FDA) has approved TRULANCE ®(plecanatide) 3 mg tablet for the...

Read More »

Jan25Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares »


Dublin, Ireland and Trevose, Pa., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ:SBBP) (the “Company”) today announced that it has priced its...

Read More »

Jan17Strongbridge Biopharma plc Announces Acquisition of the U.S. and Canadian Rights to MACRILEN™ (macimorelin) from Aeterna Zentaris »


-- MACRILEN is the First and Only FDA-Approved Oral Drug Indicated For the Diagnosis of Adult Growth Hormone Deficiency, a Rare Endocrine Disorder -- -- MACRILEN is Strongbridge...

Read More »